Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Oct;2(10):2340-58.
doi: 10.3390/toxins2102340. Epub 2010 Oct 11.

Genomic damage in endstage renal disease-contribution of uremic toxins

Nicole Schupp  1 , August Heidland, Helga Stopper
Affiliations
Review

Genomic damage in endstage renal disease-contribution of uremic toxins

Nicole Schupp et al. Toxins (Basel). 2010 Oct.

Abstract

Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-α. This review provides an overview of genomic damage observed in ESRD patients, focuses on possible underlying causes and shows modulations of the damage by modern dialysis strategies and vitamin supplementation.

Keywords: dialysis; genotoxicity; uremic toxins.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., Van Lente F., Levey A.S. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047. - PubMed
    1. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M., Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93–99. - PubMed
    1. Stewart J.H., Buccianti G., Agodoa L., Gellert R., McCredie M.R., Lowenfels A.B., Disney A.P., Wolfe R.A., Boyle P., Maisonneuve P. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J. Am. Soc. Nephrol. 2003;14:197–207. doi: 10.1097/01.ASN.0000039608.81046.81. - DOI - PubMed
    1. Teschner M., Garte C., Rückle-Lanz H., Mader U., Stopper H., Klassen A., Heidland A. Incidence and spectrum of malignant disease among dialysis patients in North Bavaria. Dtsch. Med. Wochenschr. 2002;127:2497–2502. - PubMed
    1. Kan E., Undeger U., Bali M., Basaran N. Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of Vitamin E supplementation. Mutat. Res. 2002;520:151–159. - PubMed